SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NNVC - NanoViricides, Inc.
NNVC 1.850-2.6%Nov 7 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Straynut who wrote (12666)3/6/2020 12:26:59 PM
From: drkaz1 Recommendation

Recommended By
Savant

  Read Replies (1) of 12871
 
The problems - of course remain,...

1) NNVC doesn't actually have a license from Diwan/Theracour to produce a medicine for this virus or group of viruses at this stage,... and that would have to be 'negotiated' in some way.

2) NNVC doesn't have any actual test data - model organism or otherwise - of which we are aware that indicates that their proposed medicine does anything useful,... so they would have to spend a year or more generating some actual data.

3) NNVC doesn't have any toxicity testing data for an ingested or injected version of any of their drugs,... so they would have to first make enough quantity (this capability is debatable of course) to do toxicity testing and then do the testing.

4) Aren't they actually supposed to be working on clinical testing for their topical anti-shingles treatment currently?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News